Ozempic is synonymous with weight loss for many people. Doctors explain benefits and risks of semaglutide and other GLP-1 ...

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A popular diabetes drug just got a major new approval — and it could be a game-changer for millions of Americans at risk for kidney failure.

Now, one type of weight-loss medication is proving helpful with another health issue. In a study published Feb. 12 in JAMA ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

Tirzepatide, found in Mounjaro and Zepbound, mimics both GIP and GLP-1 hormones to activate insulin production. Semaglutide, ...

Dr Craig Koniver, a family physician in Charleston, South Carolina, said he currently has 200 patients using the same method ...

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

Novo Nordisk's 2024 earnings exceeded estimates, with strong performance in diabetes, obesity, and rare disease segments.

Pharma giant Novo Nordisk, the company behind Wegovy and Ozempic, expects to launch six products in the next five years. Leading the pack of new drugs will be CagriSema.